🫁 Pulmonary Tuberculosis Chemotherapy Regimen
UseSpecific treatment and doses follow current guidelines and local protocols; this page does not list them. [Pe…
SourceWorld Health Organization. WHO consolidated guidelines on tuberculosis: drug-susceptible and drug-r…
This-shift next steps
After scoring: open the scene pack, peer scores, and the matching pathway. Local reference — no HIS write.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
Methodology · worked example, guidelines & full notes
Resistance screening before treatment is emphasized so retreatment and drug-resistant cases are never managed by blindly reusing the first-line regimen. (original synthesis · not guideline verbatim)
When to use
Specific treatment and doses follow current guidelines and local protocols; this page does not list them. [Pending update] Unsourced specific doses/regimens on this page are temporarily hidden pending item-by-item review against the cited guideline texts.
How it works
New susceptible Retreatment RR/MDR → individualized regimen by susceptibility, specialist-managed.
Key points
- Resistance screening before treatment is emphasized so retreatment and drug-resistant cases are never managed by blindly reusing the first-line regimen. (original synthesis · not guideline verbatim)
- DOT and full-course adherence underpin all regimens.
- Monitoring covers hepatotoxicity (H/R/Z), vision/color vision (E), and uric acid (Z).
References
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Treatment category | Retreatment |
|---|
→RegimenRetreatment regimen (susceptibility-guided)
- Recommended regimen：must adjust per drug-susceptibility results
- Principles：early, combined, appropriate dose, regular, complete; resistance screening and susceptibility testing before retreatment, avoid blindly reusing the first-line regimen
- Monitoring：Resistance screening (molecular testing) before and during treatment; monitor liver function (H/R/Z), vision and color vision (E), uric acid (Z), sputum conversion; manage adverse drug reactions promptly
| Treatment category | New (susceptible) |
|---|
→RegimenInitial regimen: see the cited guideline (pending update)
- Recommended regimen：Specific treatment and doses follow current guidelines and local protocols; this page does not list them. [Pending update] Unsourced specific doses/regimens on this page are temporarily hidden pending item-by-item review against the cited guideline texts.
- Principles：early, combined, appropriate dose, regular, complete; sputum at end of month 2 and 5; if still positive at month 2,
- Monitoring：Resistance screening (molecular testing) before and during treatment; monitor liver function (H/R/Z), vision and color vision (E), uric acid (Z), sputum conversion; manage adverse drug reactions promptly
Verification & sources · governance
FAQ
Frequently asked questions
- What are the limits and cautions when using Pulmonary Tuberculosis Chemotherapy Regimen?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- Does Pulmonary Tuberculosis Chemotherapy Regimen upload patient data? Where is it calculated?
- Calculation runs locally in the browser; inputs and results are not uploaded. For licensed clinicians only; interpret with history, investigations and local protocols — not a diagnosis or prescription.